Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study
Journal of Nephrology · 2024
DOI: 10.1007/s40620-024-01889-9 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Nephrology, 2024. Verfasst von Simona Simone und 21 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy. Hauptthemen laut MEDLINE: Kidney Transplantation, Antibodies, Monoclonal, Humanized, COVID-19, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Bari Aldo Moro.
Abstract (Originalsprache)
Background
Immunocompromised patients show an impaired vaccine response and remain at high risk of severe COVID-19, despite vaccination. Neutralizing monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed for prophylaxis and treatment. The combination tixagevimab/cilgavimab (AZD7442) has been authorized for emergency use as pre-exposure prophylaxis for COVID-19, but data on safety and efficacy in kidney transplant recipients during the Omicron period are limited.
Methods
We conducted a multicenter retrospective cohort study including 253 kidney transplant recipients, of whom 98 were treated with tixagevimab/cilgavimab 150 mg/150 mg and 155 who received only four doses of the BNT162b2 mRNA vaccine.
Results
Only 13.3% of patients developed SARS-CoV-2 infection after the administration of tixagevimab/cilgavimab; in comparison, 34.2% of patients had been infected after the fourth dose of vaccine ( p = 0.00013). Most infected patients in the AZD7442 group remained asymptomatic (92.3% vs 54.7%), 7.7% had mild symptoms and none had severe disease, need for hospitalization or died, while in the control group, 9.4% of patients had moderate or severe disease ( p = 0.04). Using Kaplan–Meier curves we demonstrated that the controls presented early infection compared to the AZD7442 group ( p = 0.000014). No changes in eGFR or proteinuria, assessed before and after the administration, were observed.
Conclusions
In conclusion, our study showed that tixagevimab/cilgavimab 150/150 mg is effective and safe in preventing infection and severe disease when administered to patients with weak or no response to COVID-19 vaccine. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy.
- Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari Aldo Moro, Bari, Italy.
- Renal Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
- Clinic Pathology Unit, University Hospital of Bari, Bari, Italy.
- Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari "Aldo Moro", 70124, Bari, Italy.
- Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy. loreto.gesualdo@uniba.it.
ORCID-Profile: Simona Simone, Virginia Pronzo, Francesco Pesce, Davide Fiore Bavaro, Barbara Infante, Annalisa Schirinzi, Antonella Panaro, Eleonora Conte, Alessandra Belati, Dario Troise, Paola Pontrelli, Francesca Conserva, Pasquale Gallo, Marco Spilotros, Giuseppe Lucarelli, Annalisa Saracino, Giovanni Stallone, Francesca Di Serio, Pasquale Ditonno, Loreto Gesualdo
Förderung
- Università degli Studi di Bari Aldo Moro
Zitieren
APA
Simone, S., Pronzo, V., Pesce, F., Bavaro, D. F., Infante, B., Mercuri, S., Schirinzi, A., Panaro, A., Conte, E., Belati, A., Troise, D., Pontrelli, P., Conserva, F., Gallo, P., Panico, M., Spilotros, M., Lucarelli, G., Saracino, A., Stallone, G., …, & Gesualdo, L. (2024). Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study. Journal of Nephrology. https://doi.org/10.1007/s40620-024-01889-9
Vancouver
Simone S, Pronzo V, Pesce F, Bavaro DF, Infante B, Mercuri S, et al. Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study. Journal of Nephrology. 2024. doi:10.1007/s40620-024-01889-9
BibTeX
@article{Simone2024,
author = {Simone, Simona and Pronzo, Virginia and Pesce, Francesco and Bavaro, Davide Fiore and Infante, Barbara and Mercuri, Silvia and Schirinzi, Annalisa and Panaro, Antonella and Conte, Eleonora and Belati, Alessandra and Troise, Dario and Pontrelli, Paola and Conserva, Francesca and Gallo, Pasquale and Panico, Maddalena and Spilotros, Marco and Lucarelli, Giuseppe and Saracino, Annalisa and Stallone, Giovanni and Di Serio, Francesca and Ditonno, Pasquale and Gesualdo, Loreto},
title = {Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study},
journal = {Journal of Nephrology},
year = {2024},
doi = {10.1007/s40620-024-01889-9}
}
EUVIMED